| Name | Acetazolamide sodium |
| Description | Acetazolamide sodium (OT-302 sodium) is a potent carbonic anhydrase (CA)IX inhibitor with diuretic, antigonococcal, and antihypertensive activity and may be used for indications such as epilepsy, glaucoma, edema, and altitude sickness. |
| In vitro | The combination of Acetazolamide sodium (0-160 μM) with MS-275 (0.75 μM) exhibited dose-dependent inhibition of growth, induced cell cycle arrest and apoptosis, and reduced migration ability in NB cell line SH-SY5Y[1]. |
| In vivo | In preclinical xenograft models, treatment with AZ (40 mg/kg), MS-275 (20 mg/kg), and AZ + MS-275 (40 + 20 mg/kg) for 14 days significantly inhibited tumor growth in vivo. The expression of HIF-1α and CAIX markedly decreased, while apoptosis in NB xenograft cells of SH-SY5Y significantly increased[1]. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : 80 mg/mL (327.56 mM), Sonication is recommended.
DMSO : 80 mg/mL (327.56 mM), Sonication is recommended.
|
| Keywords | CarbonicAnhydrase | Carbonic anhydrase IX | Carbonic Anhydrase |
| Inhibitors Related | Neomycin sulfate | Aceglutamide | Hemin | D(+)-Raffinose pentahydrate | Guanidine hydrochloride | Sulfamethoxazole sodium | Terbinafine hydrochloride | Hydroxychloroquine | Hyaluronic acid sodium (MW 20 kDa) | Dimethyl sulfoxide | Sodium diacetate | Sodium bicarbonate |
| Related Compound Libraries | Glycometabolism Compound Library | Bioactive Compound Library | Approved Drug Library | Drug-induced Liver Injury (DILI) Compound Library | Toxic Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Anti-Bacterial Compound Library | FDA-Approved Drug Library | Metabolism Compound Library | Bioactive Compounds Library Max | NMPA-Approved Drug Library |
United States
